These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37000142)

  • 21. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
    Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multidimensional pan-cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma.
    Wei S; Lu K; Xing J; Yu W
    FASEB J; 2023 Apr; 37(4):e22849. PubMed ID: 36884358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    Zhang X; Wu Z; Ma K
    BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
    Liu X; Chen L; Zhang T
    Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Expression of
    Deng H; Huang Y; Wang L; Chen M
    Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the cell cycle characteristics of non-small cell lung cancer and its relationship with tumor immune microenvironment, cell death pathways, and metabolic reprogramming.
    Cao S; Xiao S; Zhang J; Li S
    Front Endocrinol (Lausanne); 2023; 14():1147366. PubMed ID: 37091844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
    Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
    Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
    Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
    Front Immunol; 2022; 13():857308. PubMed ID: 35345673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
    Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
    Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-mesenchymal transition-related lncRNAs associated with prognosis and immune cell infiltration in lung adenocarcinoma.
    Zhang Q; Wu X; Sun Y; Yang L; Wang Z; Yang Y; Zhao X; Zhang X
    Am J Transl Res; 2022; 14(10):7308-7323. PubMed ID: 36398231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy.
    Feng M; Cui H; Tu W; Li L; Gao Y; Chen L; Li D; Chen X; Xu F; Zhou C; Cao Y
    Front Genet; 2022; 13():975381. PubMed ID: 36105075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets.
    Fu X; Ji F; He Q; Qiu X
    J Immunol Res; 2022; 2022():5826741. PubMed ID: 35791393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis.
    Wang W; He J; Lu H; Kong Q; Lin S
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32519739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.